SCHEMBL3226263

SCHEMBL3226263

CC1CCCC(C(C)CCO)C1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.31
TRPM8 Q7Z2W7 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22580013 0.88 TRPA1 (0.36) TRPA1TRPM8
SCHEMBL8022668 0.83
SCHEMBL15659845 0.82
SCHEMBL14155010 0.81
SCHEMBL12321189 0.80 KDM4E (0.32)
SCHEMBL12321242 0.80 KDM4E (0.32)
SCHEMBL12321643 0.80 KDM4E (0.32)
SCHEMBL12321609 0.80 KDM4E (0.32)
SCHEMBL12321602 0.80 KDM4E (0.32)
SCHEMBL8009642 0.79 SHBG (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140142343-A1 Novel Fragrance Compounds GIVAUDAN NEDERLAND SERVICES B.V. (CH) 2014-05-22 US disclosed
US-20140142343-A1 Novel Fragrance Compounds GIVAUDAN NEDERLAND SERVICES B.V. (CH) 2014-05-22 US disclosed
US-20140142343-A1 Novel Fragrance Compounds GIVAUDAN NEDERLAND SERVICES B.V. (CH) 2014-05-22 US disclosed
US-8709994-B2 Fragrance compounds GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2014-04-29 US disclosed
EP-2077986-B1 NOVEL FRAGRANCE COMPOUNDS GIVAUDAN NEDERLAND SERVICES BV (NL) 2013-12-04 EP disclosed
EP-2657218-A1 Novel Fragrance Compounds Givaudan Nederland Services B.V. (NL) 2013-10-30 EP disclosed
EP-2657218-A1 Novel Fragrance Compounds Givaudan Nederland Services B.V. (NL) 2013-10-30 EP disclosed
US-8475999-B2 Compound and photoresist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-02 US disclosed
US-8173353-B2 Sulfonium compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-8173353-B2 Sulfonium compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100248135-A1 SULFONIUM COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-30 US disclosed
US-20100248135-A1 SULFONIUM COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-30 US disclosed
US-20100069287-A1 Novel Fragrance Compounds GIVAUDAN NEDERLAND SERVICES B.V. (CH) 2010-03-18 US disclosed
US-20100069287-A1 Novel Fragrance Compounds GIVAUDAN NEDERLAND SERVICES B.V. (CH) 2010-03-18 US disclosed
US-20100069287-A1 Novel Fragrance Compounds GIVAUDAN NEDERLAND SERVICES B.V. (CH) 2010-03-18 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed
EP-2077986-A1 NOVEL FRAGRANCE COMPOUNDS Givaudan Nederland Services B.V. (NL) 2009-07-15 EP disclosed
WO-2008053148-A1 NOVEL FRAGRANCE COMPOUNDS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-05-08 WO disclosed
WO-2008053148-A1 NOVEL FRAGRANCE COMPOUNDS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100248135-A1 SULFONIUM COMPOUND PFAS, F12, AFF1 TRPA1 71/4885TRPM8 1208/4885
US-20100069287-A1 Novel Fragrance Compounds C1S, C5, FADS1 TRPA1 277/4885TRPM8 163/4885
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 TRPA1 2535/4885TRPM8 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.